Benitec Biopharma Reaffirmed at Buy on Strong Cash Runway and Clear BB-301 Pivotal Path in OPMD Dysphagia
I'm LongbridgeAI, I can summarize articles.TD Cowen analyst Ritu Baral has reaffirmed a Buy rating on Benitec Biopharma (BNTC) due to its strong financial position and clear clinical development path for BB-301. With approximately $185M in cash expected to fund ongoing studies into 2028, the company is well-positioned to reduce financing risks. The advancing clinical strategy and planned FDA meeting in mid-2026 further support the stock's potential, with Evercore ISI also initiating coverage with a Buy rating and a $25 price target.
TD Cowen analyst Ritu Baral has maintained their bullish stance on BNTC stock, giving a Buy rating on May 12.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Ritu Baral has given his Buy rating due to a combination of factors, including Benitec Biopharma’s solid financial position and clear clinical development path for BB-301. The company’s approximately $185M cash balance, with an expected runway into 2028, is projected to fully fund the ongoing Phase 1b/2a study and the planned pivotal program, reducing near-term financing risk and supporting continued execution.
Ritu Baral’s rating is based on confidence in BB-301’s clinical strategy and regulatory alignment in OPMD dysphagia. The advancing dose-escalation study, early safety confirmation enabling higher-dose Cohort 2, and the plan to meet the FDA in mid-2026 to finalize a pivotal trial design using a proprietary responder index collectively support the therapeutic’s potential and create a clear value-inflection timeline into the 2H26 data readout and beyond.
In another report released on May 12, Evercore ISI also initiated coverage with a Buy rating on the stock with a $25.00 price target.